Thalidomide inhibits NF-kB by suppressing IkB kinase activity [36] and has been used to treat paradoxical reaction in CNS-TB [37, 38], but its considerable side effects such as teratogenicity and peripheral neuropathy mean that its potential as use for a host-directed therapy will be very limited. The gene discussed is NFKB1; the disease is tuberculosis.